Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Summary not available.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in Oppenheimer’s 32nd Annual Healthcare Conference on March 15-16, 2022. The management team is scheduled to present on March 15 at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days afterwards. Organogenesis focuses on regenerative medicine, offering advanced wound care and surgical products designed to meet various patient needs.
Organogenesis Holdings reported robust financial results for Q4 2021 and the fiscal year ending December 31, 2021. Q4 net revenue reached $128.6 million, a 20% increase from Q4 2020, mainly driven by a 30% growth in Advanced Wound Care products. Total net revenue for 2021 was $468.1 million, a 38% rise year-over-year. Net income soared to $51.7 million in Q4, compared to $18.3 million a year earlier. The company forecasted revenue for 2022 between $485 million and $515 million, indicating a expected growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has appointed Michael J. Driscoll, Ed.D. to its Board of Directors, effective February 15, 2022. Dr. Driscoll, an independent director, will contribute to the Audit and Nominating Committees. He brings extensive experience with 28 years in the financial services sector and 10 years in academia. His previous roles include dean of Mount St. Mary’s University and a senior executive at Adelphi University. The company's management expressed confidence in his strategic insights to bolster its operations in regenerative medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leader in regenerative medicine, will participate in two upcoming investor conferences. Management will engage in a virtual fireside chat on February 16 at 1:30 p.m. ET during the BTIG Virtual MedTech Conference. Additionally, they will partake in another virtual chat on February 18 at 8:40 a.m. ET for the 11th Annual SVB Leerink Global Healthcare Conference. Live webcasts will be accessible via the respective conference websites, with the second's archive available for 30 days post-event.
Organogenesis Holdings (Nasdaq: ORGO) will announce its fourth quarter and fiscal year 2021 financial results on March 1, 2022, after market close. Management will discuss these results in a conference call at 5:00 p.m. ET, which is open to participants via a dedicated phone line or a live webcast on the investor relations section of their website. A replay will be available for two weeks post-call. Organogenesis specializes in regenerative medicine, focusing on solutions for advanced wound care and surgical and sports medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the appointment of Prathyusha Duraibabu to its Board of Directors as of November 19, 2021. Ms. Duraibabu brings over 24 years of expertise in technology and healthcare, having held senior roles at global biotechnology firms. Currently the CFO of Sangamo Therapeutics, she has also served as Corporate Controller at Pacific Biosciences. The addition is expected to enhance the Board's strategic insight and oversight, particularly within the Audit Committee.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q3 2021 net revenue of $113.8 million, a 13% increase year-over-year. Advanced Wound Care products drove revenue growth, contributing $107.3 million, up 19% compared to Q3 2020. However, Surgical & Sports Medicine revenue fell 41% to $6.4 million. Net income decreased to $12.6 million from $20.8 million in Q3 2020. Operating expenses rose 30% to $71.3 million, impacting profitability. The company forecasts 2021 net revenue between $458 million and $470 million, a 35% to 39% increase year-over-year.
Organogenesis Holdings (Nasdaq: ORGO) will participate in the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021. A fireside chat featuring company management is scheduled for November 11 at 9:40 a.m. ET. The event will be held virtually, and a live audio webcast will be accessible via the ‘Upcoming Events’ section on Organogenesis’s Investor Relations page. An archived version of the webcast will be available for 30 days post-conference.
Organogenesis specializes in regenerative medicine, offering bioactive products for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will showcase advanced wound care research at the 2021 Symposium on Advanced Wound Care Fall Conference in Las Vegas from October 29-31. Key presentations include a lunch symposium discussing in vivo data on PuraPly technology and a session on dermal substitutes post-Mohs surgery. The company also highlights its Adjustable Curette, aimed at enhancing wound debridement. Organogenesis, a leader in regenerative medicine, focuses on innovative solutions for advanced wound care and surgical applications.